Skip to main content
SpringerLink
Log in

I-131 Meta Iodobenzylguanidine Therapy

  • Chapter
  • First Online:
Therapeutic Nuclear Medicine

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 2645 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Altman A, Kissel M, Zitzmann K et al (2003) Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med 44:973–980

    Google Scholar 

  • Barrett JA, Joyal JL, Hillier SM et al (2010) Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharma 25:299–308

    Article  CAS  Google Scholar 

  • Bayer M, Kuci Z, Schomig E et al (2009) Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells. Nucl Med Biol 36:287–294

    Article  CAS  PubMed  Google Scholar 

  • Beierwaltes WH (1987) Treatment of neuroblastoma with 131I-mIBG—dosimetric problems and perspectives. Med Pediatr Oncol 15:188–191

    Article  CAS  PubMed  Google Scholar 

  • Bestagno M, Guerra P, Puricelli GP et al (1987) Treatment of neuroblastoma with 131-I-meta-iodobenzylguanidine: the experience of an Italian study group. Med Pediatr Oncol 15:203–204

    Article  CAS  PubMed  Google Scholar 

  • Bombardieri E, Giammarile F, Aktolun C et al (2010) I-131/I-123 metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37:2436–2446

    Article  PubMed  Google Scholar 

  • Buckley SE, Chittenden SJ, Saran FH et al (2009) Whole-body dosimetry for individualized treatment planning of 131I-mIBG radionuclide therapy for neuroblastoma. J Nucl Med 50:1518–1524

    Article  CAS  PubMed  Google Scholar 

  • Buscombe JR, Cwikla JB, Caplin ME et al (2005) Long-term efficacy of low-activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl Med Commun 26:969–976

    Article  CAS  PubMed  Google Scholar 

  • Castellani MR, Di Bartolomeo M, Maffioli I et al (1991) [131I]Metaiodobenzylguanidine therapy in carcinoid tumours. J Nucl Biol Med 35:349–351

    CAS  PubMed  Google Scholar 

  • Castellani MR, Seghezzi A, Chiesa C et al (2010) I-131 MIBG treatment of phaeochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging 54(1):100–113

    CAS  PubMed  Google Scholar 

  • Coleman RE, Stubbs JB, Barrett JA et al (2009) Radiation dosimetry, pharmacokinetics, and safety of ultratrace-iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharma 24:469–475

    Article  CAS  Google Scholar 

  • Cottino F, Mussa GC, Madon E et al (1987) 131I-meta-iodobenzylguanidine treatment in neuroblastoma: report of two cases. Med Pediatr Oncol 15:216–219

    Article  CAS  PubMed  Google Scholar 

  • Cunningham SH, Mairs RJ, Wheldon TE et al (1998) Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 77:2061–2068

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ et al (2007) A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466–3469

    Article  PubMed  Google Scholar 

  • De Souza JA, Busaidy N, Zimrin A et al. (2010) Phase II trial of sunitinib in medullary thyroid cancer. J Clin Oncol 28:15 s (suppl; abstr 5504)

    Google Scholar 

  • Dubois SG, Chesler L, Groshen S (2012) Phase I study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. Clin Cancer Res. Mar 16 EPub ahead of print

    Google Scholar 

  • Fischer M, Wehinger H, Kraus C et al (1987) Treatment of neuroblastoma with 131I-meta-iodobenzylguanidine: experience of the Munster/Kassel group. Med Pediatr Oncol 15:196–198

    Article  CAS  PubMed  Google Scholar 

  • Gaze MN, Huxham IM, Mairs RJ et al (1991) Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging. Int J Cancer 47:875–880

    Article  CAS  PubMed  Google Scholar 

  • Gaze MN, Mairs RJ, Boyack SM et al (1992) 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 66:1048–1052

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gaze MN, Chang YC, Flux GD et al (2005) I-131 metaiodobenzylguanidine with topotecan asa radiosensitiser in children with metastatic neuroblastoma. Cancer Biother Radiopharm 20:195–199

    Article  CAS  PubMed  Google Scholar 

  • Gaze MN, Alspach A, Biassoni L et al. (2012) 131I-meta iodobenzylguanidine and topotecan in neuroblastoma (MATIN): audit of an innovative treatment schedule in five international society of paediatric oncology –Europe neuroblastoma (SIOPEN) centres. Eur J Cancer (in press)

    Google Scholar 

  • Goldberg SS, DeSantes K, Huberty JP et al (1998) Engraftment after myeloablative doses of I-131 metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Paediatr Oncol 30:339–346

    Article  CAS  Google Scholar 

  • Gonias S, Goldsby R, Mathay KK et al (2009) Phase II study of I-131 metaiodobenzylguanidine therapy for patients with metastatic phaeochromocytoma and paraganglioma. J Clin Oncol 27:4162–4168

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Grunwald F, Ezziddin S (2010) I-131 metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumours. Semin Nucl Med 40:153–163

    Article  PubMed  Google Scholar 

  • Hartmann O, Lumbruso J, Lemerle J et al (1987) Therapeutic use of 131I-meta-iodobenzylguanidine (mIBG) in neuroblastoma: a phase II study in nine patients. Med Pediatr Oncol 15:205–211

    Article  CAS  PubMed  Google Scholar 

  • Hickeson MP, Charron M, Maris JM et al (2004) Paediatr Blood Cancer 42:268–274

    Article  Google Scholar 

  • Hoefnagel CA (1999) Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 43:336–343

    CAS  PubMed  Google Scholar 

  • Hoefnagel CA, Lewington VJ (2004) mIBG therapy. In: Ell PJ, Gambhir SS (eds) Nuclear medicine in clinical diagnosis and treatment, 3rd edn). Churchill Livingstone, pp 445–457

    Google Scholar 

  • Hoefnagel CA, de Kraker J, Voute PA et al (1991) Preoperative 131I metaiodobenzylguanidine therapy of neuroblastoma at diagnosis (“MIBG de novo”). J Nucl Biol Med 35:248–251

    CAS  PubMed  Google Scholar 

  • Hoefnagel A, de Kraker J, Voute PA et al (1994) 131I mIBG as first line treatment in high risk neuroblastoma patients. Nucl Med Commun 15:712–717

    Article  CAS  PubMed  Google Scholar 

  • Howard JP, Maris JM, Kersun LS et al. (2005) Tumor response and toxicity with multiple infusions of high dose (131)I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 44:232–239

    Google Scholar 

  • Huang H, Abraham J, Hung E et al (2008) Treatment of malignant phaeochromocytoma/paraganglioma with cyclophosphamide, vincristine and dacarbazine: recommendation from a 22 year follow up of 18 patients. Cancer 113(8):2020–2028

    Article  CAS  PubMed  Google Scholar 

  • Khan MU, Morse M, Coleman RE (2008) Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of neuroendocrine tumours. Q J Nucl Med Mol Imaging 52(4):441–454

    CAS  PubMed  Google Scholar 

  • Knickmeier M (2001) Two years experience using no carrier added I-123 metaiodobenzylguanidine in clinical studies II. Eur J Nucl Med 28:941

    Article  CAS  PubMed  Google Scholar 

  • Ladenstein R, Philip T, Lasset C et al (1998) Multivariate analysis of risk factors in stage IV neuroblastoma patients over the age of 1 year treated with megatherapy and stem cell transplantation: a report from the European bone marrow transplantation solid tumour registry. J Clin Oncol 16:953–965

    CAS  PubMed  Google Scholar 

  • Lam ET, Ringel MD, Kloos RT et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323–2330

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lashford LS, Lewis IJ, Fielding SL et al (1992) Phase I/II study of Iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom children’s cancer study group investigation. J Clin Oncol 10:1889–1896

    CAS  PubMed  Google Scholar 

  • Leung A, Shapiro B, Hattner R et al (1997) Specificity of radioiodinated metaiodobenzylguanidine for neural crest tumours in childhood. J Nucl Med 38:1352–1357

    CAS  PubMed  Google Scholar 

  • Loh KC, Fitzgerald PA, Matthay KK et al (1997) The treatment of malignant phaeochromocytomas with iodine-131 metaiodobenzylguanidine (I-131 MIBG). a comprehensive review of 116 reported patients. J Endocrinol Investig 20:648–681

    Article  CAS  Google Scholar 

  • Mairs RJ, Boyd M (2008) Optimising MIBG therapy of neuroendocrine tumours: preclinical evidence of dose maximisation and synergy. Nucl Med Biol 35: SI:9–SI:20

    Google Scholar 

  • Mairs RJ, Livingstone AL, Gaze MN et al (1994) Prediction of accumulation of I-131 metaiodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Brit J Cancer 70:97–101

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mastrangelo R, Tomesello A, Lasorella A et al (1997) Optimal use of the I-131 metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neuro Oncol 31:153–158

    Article  CAS  Google Scholar 

  • Mastrangelo S, Tomesello A, Diociaiuti L et al (2001) Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining I-131 mIBG and multiple drug therapy. Br J Cancer 84(4):460–464

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Matthay KK, DeSantes K, Hasegawa B et al (1998) Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16:229–236

    CAS  PubMed  Google Scholar 

  • Matthay KK, Villablanca JG, Seeger R et al (1999) Children’s cancer group: treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13 cis retinoic acid. N Engl J Med 341:1165–1173

    Article  CAS  PubMed  Google Scholar 

  • Matthay KK, Tan JC, Villablanca JG et al (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. J Clin Oncol 24:500–506

    Article  CAS  PubMed  Google Scholar 

  • Matthay KK, Yanik G, Messina J et al (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25:1054–1060

    Article  CAS  PubMed  Google Scholar 

  • Matthay KK, Quach A, Huberty J et al (2009) Iodine-131—metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy Phase I study. J Clin Oncol 27:1020–1025

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McCluskey AG, Boyd M, Gaze MN et al (2005a) I-131 mIBG with topotecan: a rationale for combination therapy for neuroblastoma. Cancer Lett 228:221–227

    Article  CAS  PubMed  Google Scholar 

  • McCluskey AG, Boyd M, Ross SC et al (2005b) I-131 metaiodobenzylguanidine and topotecan combination treatment of tumours expressing the noradrenaline transporter. Clin Cancer Res 11:7929–7937

    Article  CAS  PubMed  Google Scholar 

  • Mukherjee JJ, Kaltsas GA, Islam N et al. (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglionoma,and medullary carcinoma of the thyroid with 131-I-meta-iodobenzylguanidine. Clin Endocrinol. 55:47–60

    Google Scholar 

  • Navalkissoor S, Alhashimi DM, Quigley AM et al (2010) Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37:904–912

    Article  PubMed  Google Scholar 

  • Nguyen C, Faraggi M, Giraudet AL et al (2004) Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45:1660–1668

    CAS  PubMed  Google Scholar 

  • O’Donoghue JA, Wheldon TE (1988) Predicted allowable doses to normal organs for biologically targeted radiotherapy. Br J Radiol 61:264–266

    Article  PubMed  Google Scholar 

  • O’Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumour size and curability for uniformly targeted therapy with beta emitting radionuclides. J Nucl Med 36:1902–1909

    PubMed  Google Scholar 

  • O’Donoghue JA, Sgouros G, Dvigi CR et al (2000) Single dose versus fractionated radioimmunotherapy; model comparisons for uniform dosimetry. J Nucl Med 41(3):538–547

    PubMed  Google Scholar 

  • Owens J, Bolster AA, Prosser J et al (2000) No carrier added I-123 mIBG: an initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 21:437–440

    Article  CAS  PubMed  Google Scholar 

  • Prymer DA, Barrett JA, Coleman RE et al. (2011). Preliminary data from an ongoing phase IIb study of no carrier added 131I-iobenguane (nca-MIBG) in patients with malignant pheochromocytoma (Pheo) J Clin Oncol 29: (suppl; abstr e21122)

    Google Scholar 

  • Rutgers M, Buitenhuis CK, van der Valk MA, Hoefnagel CA, Voute PA, Smets LA (2000) [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts. Int J Cancer 90:312–325

    Article  CAS  PubMed  Google Scholar 

  • Safford SD, Coleman RE, Gockerman JP et al (2003) Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant phaeochromocytoma and paraganglioma. Surgery 134:956–962

    Article  PubMed  Google Scholar 

  • Safford SD, Coleman RE, Gockerman JP et al (2004) Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid results in 98 patients. Cancer 101(9):1987–1993

    Article  CAS  PubMed  Google Scholar 

  • Sanguinetti M (1987) Considerations on 131I-meta-iodobenzylguanidine therapy of six children with neuroblastoma. Med Pediatr Oncol 15:212–215

    Article  Google Scholar 

  • Sarnaan NA, Hickey RC, Shutts PE (1988) Diagnosis, localisation and management of phaeochromocytoma. pitfalls and follow up in 41 patients. Cancer 62:2451–2460

    Article  Google Scholar 

  • Sisson J, Shapiro B, Beierwaltes WH et al (1983) Treatment of malignant phaeochromocytoma with a new radiopharmaceutical. Trans Assoc Am Phys 96:209–217

    CAS  PubMed  Google Scholar 

  • Sisson JC, Shapiro B, Hutchinson RJ et al (1996) Survival of patients with neuroblastoma treated with 125-I MIBG. Am J Clin Oncol 19(2):144–148

    Article  CAS  PubMed  Google Scholar 

  • Smets LA, Loesberg C, Janssen M et al (1989) Active uptake and extravesicular storage of metaiodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 49:2941–2944

    CAS  PubMed  Google Scholar 

  • Szalat A, Fraenkel M, Doviner V et al (2011) Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine 39:160–166

    Article  CAS  PubMed  Google Scholar 

  • Treuner J, Klingebiel T, Bruchelt G et al (1987) Treatment of neuroblastoma with metaiodobenzylguanidine: results and side effects. Med Pediatr Oncol 15:199–202

    Article  CAS  PubMed  Google Scholar 

  • Troncone L, Riccardi R, Montemaggi P et al (1987) Treatment of neuroblastoma with 131I-meta-iodobenzylguanidine. Med Pediatr Oncol 15:220–223

    Article  CAS  PubMed  Google Scholar 

  • Vaidyanathan G, Zhao XG, Larsen RH et al (1997) 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. Br J Cancer 76(2):226–233

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Vaidyanathan G, Affleck DJ, Alston KL et al (2007) A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem 15(10):3430–3436

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • van santen HM, de Kraker J, Vulsmer T et al. (2005) Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 1767–1774

    Google Scholar 

  • Voûte PA, Hoefnagel CA, de Kraker J et al (1987) Radionuclide therapy of neural crest tumours. Med Pediatr Oncol 15:192–195

    Article  PubMed  Google Scholar 

  • Weber W, Weber J, Senekowitsch-Schmidtke R (1996) Therapeutic effect of m-[131I]-and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Res 56:5428–5434

    CAS  PubMed  Google Scholar 

  • Wells SA, Robinson BG, Gagel RF (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134–141

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. London, UK

    Val Lewington

Authors
  1. Val Lewington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Val Lewington .

Editor information

Editors and Affiliations

  1. THERANOSTICS Center for Molecular, Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Bad Berka, Germany

    Richard P. Baum

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lewington, V. (2013). I-131 Meta Iodobenzylguanidine Therapy. In: Baum, R. (eds) Therapeutic Nuclear Medicine. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2012_784

Download citation

  • DOI: https://doi.org/10.1007/174_2012_784

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-36718-5

  • Online ISBN: 978-3-540-36719-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation